SCHEMBL6646013

SCHEMBL6646013

Cc1ccc2cc(Cl)[nH]c(=O)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SAE1 Q9UBE0 2/20 0.46
UBA2 Q9UBT2 2/20 0.46
CDC25B P30305 2/20 0.46
UBE2I P63279 1/20 0.46
TYMS P04818 1/20 0.43
DAO P14920 2/20 0.42
DDO Q99489 1/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647787 0.85 LMNA (0.53) SAE1UBA2CDC25BUBE2IDAO
SCHEMBL824649 0.81 KDM4E (0.63) SAE1UBA2CDC25BUBE2ITYMS
SCHEMBL6644990 0.78 PIM1 (0.43) CDC25BTYMSGAALMNATUBB4A
SCHEMBL1719929 0.78 TYMS (0.50) SAE1UBA2CDC25BUBE2ITYMS
SCHEMBL14867343 0.75 HPGD (0.57) SAE1UBA2CDC25BUBE2IKDM4E
SCHEMBL29784203 0.75 KDM4E (0.60) SAE1UBA2CDC25BUBE2IKDM4E
SCHEMBL150458 0.75 KDM4E (0.60) SAE1UBA2CDC25BUBE2IKDM4E
SCHEMBL6645110 0.73 PARP1 (0.49) SAE1UBA2CDC25BUBE2ITYMS
SCHEMBL28629567 0.73 KDM4E (0.59) SAE1UBA2CDC25BUBE2IKDM4E
SCHEMBL30160749 0.73 KDM4E (0.59) SAE1UBA2CDC25BUBE2IKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 SAE1 509/4885UBA2 2502/4885CDC25B 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.